Getinge AB (publ) (GNGBY) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Getinge AB (publ) (GNGBY) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 47/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Getinge AB (publ) (GNGBY) Resumen de Asistencia Médica y Tuberías
Getinge AB (publ) provides solutions for operating rooms, intensive-care units, and sterilization departments, with a global presence and focus on acute care, life science, and surgical workflows. The company's diverse product portfolio and extensive distribution network position it as a key player in the medical devices sector.
Tesis de Inversión
Getinge AB (publ) presents a notable research candidate due to its established market position in the medical devices sector and its diversified product portfolio. The company's focus on acute care, life science, and surgical workflows provides exposure to multiple growth areas within healthcare. With a P/E ratio of 22.79 and a dividend yield of 2.43%, Getinge offers a blend of value and income. Ongoing catalysts include increasing demand for healthcare solutions driven by an aging global population and advancements in medical technology. However, potential risks include currency fluctuations and competition from other medical device manufacturers.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $5.43 billion reflects Getinge's significant presence in the medical device industry.
- Profit margin of 6.5% indicates efficient operations and profitability.
- Gross margin of 45.9% demonstrates the company's ability to maintain pricing power and manage costs.
- Dividend yield of 2.43% provides an income stream for investors.
- Beta of 0.88 suggests lower volatility compared to the overall market.
Competidores y Pares
Fortalezas
- Diversified product portfolio
- Global presence and distribution network
- Strong brand reputation
- Focus on innovation
Debilidades
- Exposure to currency fluctuations
- Dependence on healthcare spending
- Competition from larger medical device companies
- Potential for product recalls
Catalizadores
- Ongoing: Increasing demand for healthcare solutions driven by an aging global population.
- Ongoing: Advancements in medical technology and innovation.
- Upcoming: Potential strategic acquisitions to expand product portfolio and market reach.
- Ongoing: Expansion in emerging markets with developing healthcare infrastructure.
- Ongoing: Development of integrated solutions combining hardware, software, and services.
Riesgos
- Potential: Currency fluctuations impacting revenue and profitability.
- Potential: Changes in healthcare regulations and reimbursement policies.
- Ongoing: Competition from other medical device manufacturers.
- Potential: Product recalls or safety concerns.
- Potential: Economic downturns affecting healthcare spending.
Oportunidades de crecimiento
- Expansion in Emerging Markets: Getinge can leverage its existing distribution network to expand its presence in emerging markets, where healthcare infrastructure is developing and demand for medical devices is increasing. This expansion can drive revenue growth and diversify the company's geographic exposure. The global medical device market is expected to reach $600 billion by 2028, offering significant opportunities for growth.
- Technological Innovation: Investing in research and development to introduce innovative products and solutions can drive growth and maintain a competitive edge. Focus areas include advanced surgical technologies, digital healthcare solutions, and personalized medicine. Continuous innovation will allow Getinge to capture market share and address evolving customer needs. Ongoing investment in R&D is crucial for long-term success.
- Strategic Acquisitions: Acquiring complementary businesses and technologies can expand Getinge's product portfolio and market reach. Strategic acquisitions can provide access to new markets, technologies, and customer segments, accelerating growth and enhancing the company's competitive position. Careful due diligence and integration are essential for successful acquisitions.
- Increased Focus on Life Science Solutions: The life science segment offers significant growth potential due to increasing demand for bioprocessing equipment and solutions. Getinge can capitalize on this trend by expanding its product offerings and strengthening its relationships with pharmaceutical and biotechnology companies. The global bioprocessing market is projected to reach $30 billion by 2027.
- Development of Integrated Solutions: Offering integrated solutions that combine hardware, software, and services can create value for customers and differentiate Getinge from competitors. Integrated solutions can improve efficiency, reduce costs, and enhance patient outcomes. This approach can also create recurring revenue streams through service contracts and software subscriptions.
Oportunidades
- Expansion in emerging markets
- Development of integrated solutions
- Strategic acquisitions
- Increasing demand for bioprocessing solutions
Amenazas
- Changes in healthcare regulations
- Economic downturns
- Technological obsolescence
- Increased competition
Ventajas competitivas
- Established brand reputation and long-standing relationships with customers.
- Extensive distribution network and global reach.
- Diversified product portfolio across multiple healthcare segments.
- Strong focus on innovation and research and development.
Acerca de GNGBY
Founded in 1904 and headquartered in Gothenburg, Sweden, Getinge AB (publ) has evolved into a global provider of medical technology solutions. The company operates through three primary segments: Acute Care Therapies, Life Science, and Surgical Workflows. The Acute Care Therapies segment offers products for critical care, including anesthesia machines, ventilators, and cardiovascular surgery solutions. The Life Science segment provides equipment and systems for sterile transfer, bioprocessing, and laboratory applications. The Surgical Workflows segment focuses on solutions for operating rooms, such as surgical tables, lighting systems, and sterile supply management. Getinge serves a global customer base through a network of proprietary sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Its comprehensive product portfolio and global reach solidify its position as a key player in the healthcare industry.
Qué hacen
- Provides equipment for operating rooms and intensive-care units.
- Offers sterilization solutions for healthcare facilities.
- Develops and manufactures bioprocessing systems for the life science industry.
- Provides surgical workflows solutions.
- Offers acute care therapies, including anesthesia and ventilation equipment.
- Provides sterile transfer systems and closure processing systems.
Modelo de Negocio
- Sells medical devices and equipment to hospitals, clinics, and research institutions.
- Provides service and maintenance contracts for its equipment.
- Offers software solutions for managing surgical workflows and bioprocessing operations.
- Generates revenue through a network of proprietary sales companies, agents, and distributors.
Contexto de la Industria
Getinge AB (publ) operates in the medical devices industry, which is characterized by continuous innovation and increasing demand driven by an aging global population and rising healthcare expenditures. The industry is competitive, with key players including Abbott Laboratories (ABT), Align Technology (ALGN), and Bio-Rad Laboratories (BIO). Getinge's focus on acute care, life science, and surgical workflows positions it to capitalize on specific growth areas within the broader medical devices market.
Clientes Clave
- Hospitals and clinics
- Research institutions
- Pharmaceutical and biotechnology companies
- Sterilization departments
Finanzas
Gráfico e información
Precio de la acción de Getinge AB (publ) (GNGBY): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows On Tuesday
· 24 mar 2020
-
Stocks That Hit 52-Week Highs On Friday
· 10 ene 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· 26 nov 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para GNGBY.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para GNGBY.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de GNGBY en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Mattias Perjos
President & CEO
Mattias Perjos serves as the President and CEO of Getinge AB (publ). Prior to joining Getinge, he held various leadership positions at other companies in the healthcare and technology sectors. His experience includes roles in sales, marketing, and general management. Perjos has a strong track record of driving growth and improving operational efficiency.
Historial: Under Mattias Perjos' leadership, Getinge has focused on strengthening its core business, expanding its presence in key markets, and investing in innovation. He has overseen the development and launch of new products and solutions, as well as strategic acquisitions to enhance the company's competitive position. His tenure has been marked by a commitment to improving patient outcomes and delivering value to shareholders.
Información de ADR de Getinge AB (publ) No patrocinado
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. GNGBY represents shares of Getinge AB (publ), a Swedish company. As an ADR, GNGBY allows U.S. investors to invest in Getinge without the complexities of cross-border transactions. Dividends are converted to U.S. dollars before distribution.
- Ticker del mercado local: Nasdaq Stockholm, Sweden
- Nivel de ADR: 1
- Ratio de ADR: 1:1
- Ticker del mercado local: GNGB
Información del mercado OTC de GNGBY
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure, and may not meet the minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to listed companies.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for fraud or manipulation
- Lack of regulatory oversight
- Higher price volatility
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings.
- Established operating history
- Reputable management team
- Audited financial statements (if available)
- Positive news coverage or industry recognition
- Clear business model and value proposition
Lo Que los Inversores Preguntan Sobre Getinge AB (publ) (GNGBY)
¿Cuáles son los factores clave para evaluar GNGBY?
Getinge AB (publ) (GNGBY) actualmente tiene una puntuación IA de 47/100, indicando puntuación baja. Fortaleza clave: Diversified product portfolio. Riesgo principal a monitorear: Potential: Currency fluctuations impacting revenue and profitability.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de GNGBY?
GNGBY actualmente puntúa 47/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de GNGBY?
Los precios de GNGBY se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre GNGBY?
La cobertura de analistas para GNGBY incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en GNGBY?
Las categorías de riesgo para GNGBY incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Currency fluctuations impacting revenue and profitability.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de GNGBY?
La relación P/E para GNGBY compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está GNGBY sobrevalorada o infravalorada?
Determinar si Getinge AB (publ) (GNGBY) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de GNGBY?
Getinge AB (publ) (GNGBY) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- The information provided is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.